Literature DB >> 18559922

Mutations in prokineticin 2 and prokineticin receptor 2 genes in human gonadotrophin-releasing hormone deficiency: molecular genetics and clinical spectrum.

Lindsay W Cole1, Yisrael Sidis, ChengKang Zhang, Richard Quinton, Lacey Plummer, Duarte Pignatelli, Virginia A Hughes, Andrew A Dwyer, Taneli Raivio, Frances J Hayes, Stephanie B Seminara, Celine Huot, Nathalie Alos, Phyllis Speiser, Akira Takeshita, Guy Van Vliet, Simon Pearce, William F Crowley, Qun-Yong Zhou, Nelly Pitteloud.   

Abstract

CONTEXT: Mice deficient in prokineticin 2(PROK2) and prokineticin receptor2 (PROKR2) exhibit variable olfactory bulb dysgenesis and GnRH neuronal migration defects reminiscent of human GnRH deficiency.
OBJECTIVES: We aimed to screen a large cohort of patients with Kallmann syndrome (KS) and normosmic idiopathic hypogonadotropic hypogonadism (IHH) for mutations in PROK2/PROKR2, evaluate their prevalence, define the genotype/phenotype relationship, and assess the functionality of these mutant alleles in vitro.
DESIGN: Sequencing of the PROK2 and PROKR2 genes was performed in 170 KS patients and 154 nIHH. Mutations were examined using early growth response 1-luciferase assays in HEK 293 cells and aequorin assays in Chinese hamster ovary cells.
RESULTS: Four heterozygous and one homozygous PROK2 mutation (p.A24P, p.C34Y, p.I50M, p.R73C, and p.I55fsX1) were identified in five probands. Four probands had KS and one nIHH, and all had absent puberty. Each mutant peptide impaired receptor signaling in vitro except the I50M. There were 11 patients who carried a heterozygous PROKR2 mutation (p.R85C, p.Y113H, p.V115M, p.R164Q, p.L173R, p.W178S, p.S188L, p.R248Q, p.V331M, and p.R357W). Among them, six had KS, four nIHH, and one KS proband carried both a PROKR2 (p.V115M) and PROK2 (p.A24P) mutation. Reproductive phenotypes ranged from absent to partial puberty to complete reversal of GnRH deficiency after discontinuation of therapy. All mutant alleles appear to decrease intracellular calcium mobilization; seven exhibited decreased MAPK signaling, and six displayed decreased receptor expression. Nonreproductive phenotypes included fibrous dysplasia, sleep disorder, synkinesia, and epilepsy. Finally, considerable variability was evident in family members with the same mutation, including asymptomatic carriers.
CONCLUSION: Loss-of-function mutations in PROK2 and PROKR2 underlie both KS and nIHH.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18559922      PMCID: PMC2567850          DOI: 10.1210/jc.2007-2654

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  35 in total

1.  Identification of two prokineticin cDNAs: recombinant proteins potently contract gastrointestinal smooth muscle.

Authors:  M Li; C M Bullock; D J Knauer; F J Ehlert; Q Y Zhou
Journal:  Mol Pharmacol       Date:  2001-04       Impact factor: 4.436

2.  Identification and molecular characterization of two closely related G protein-coupled receptors activated by prokineticins/endocrine gland vascular endothelial growth factor.

Authors:  Daniel Chi-Hong Lin; Clayton M Bullock; Frederick J Ehlert; Jin-Long Chen; Hui Tian; Qun-Yong Zhou
Journal:  J Biol Chem       Date:  2002-03-08       Impact factor: 5.157

3.  Loss-of-function mutations in FGFR1 cause autosomal dominant Kallmann syndrome.

Authors:  Catherine Dodé; Jacqueline Levilliers; Jean-Michel Dupont; Anne De Paepe; Nathalie Le Dû; Nadia Soussi-Yanicostas; Roney S Coimbra; Sedigheh Delmaghani; Sylvie Compain-Nouaille; Françoise Baverel; Christophe Pêcheux; Dominique Le Tessier; Corinne Cruaud; Marc Delpech; Frank Speleman; Stefan Vermeulen; Andrea Amalfitano; Yvan Bachelot; Philippe Bouchard; Sylvie Cabrol; Jean-Claude Carel; Henriette Delemarre-van de Waal; Barbara Goulet-Salmon; Marie-Laure Kottler; Odile Richard; Franco Sanchez-Franco; Robert Saura; Jacques Young; Christine Petit; Jean-Pierre Hardelin
Journal:  Nat Genet       Date:  2003-03-10       Impact factor: 38.330

4.  Prevalence, phenotypic spectrum, and modes of inheritance of gonadotropin-releasing hormone receptor mutations in idiopathic hypogonadotropic hypogonadism.

Authors:  M Beranova; L M Oliveira; G Y Bédécarrats; E Schipani; M Vallejo; A C Ammini; J B Quintos; J E Hall; K A Martin; F J Hayes; N Pitteloud; U B Kaiser; W F Crowley; S B Seminara
Journal:  J Clin Endocrinol Metab       Date:  2001-04       Impact factor: 5.958

5.  The role of prior pubertal development, biochemical markers of testicular maturation, and genetics in elucidating the phenotypic heterogeneity of idiopathic hypogonadotropic hypogonadism.

Authors:  Nelly Pitteloud; Frances J Hayes; Paul A Boepple; Suzzunne DeCruz; Stephanie B Seminara; David T MacLaughlin; William F Crowley
Journal:  J Clin Endocrinol Metab       Date:  2002-01       Impact factor: 5.958

6.  Idiopathic gonadotrophin deficiency: genetic questions addressed through phenotypic characterization.

Authors:  R Quinton; V M Duke; A Robertson; J M Kirk; G Matfin; P A de Zoysa; C Azcona; G S MacColl; H S Jacobs; G S Conway; M Besser; R G Stanhope; P M Bouloux
Journal:  Clin Endocrinol (Oxf)       Date:  2001-08       Impact factor: 3.478

7.  Prokineticin 2 transmits the behavioural circadian rhythm of the suprachiasmatic nucleus.

Authors:  Michelle Y Cheng; Clayton M Bullock; Chuanyu Li; Alex G Lee; Jason C Bermak; James Belluzzi; David R Weaver; Frances M Leslie; Qun-Yong Zhou
Journal:  Nature       Date:  2002-05-23       Impact factor: 49.962

Review 8.  Endocrine gland-derived VEGF and the emerging hypothesis of organ-specific regulation of angiogenesis.

Authors:  Jennifer LeCouter; Rui Lin; Napoleone Ferrara
Journal:  Nat Med       Date:  2002-09       Impact factor: 53.440

9.  Biallelic mutations in the prokineticin-2 gene in two sporadic cases of Kallmann syndrome.

Authors:  Chrystel Leroy; Corinne Fouveaut; Sandrine Leclercq; Sébastien Jacquemont; Hélène Du Boullay; James Lespinasse; Marc Delpech; Jean-Michel Dupont; Jean-Pierre Hardelin; Catherine Dodé
Journal:  Eur J Hum Genet       Date:  2008-02-20       Impact factor: 4.246

Review 10.  The AVIT protein family. Secreted cysteine-rich vertebrate proteins with diverse functions.

Authors:  Alexandra Kaser; Martina Winklmayr; Günther Lepperdinger; Günther Kreil
Journal:  EMBO Rep       Date:  2003-05       Impact factor: 8.807

View more
  94 in total

1.  Identification of two novel missense mutations in the KAL1 gene in Han Chinese subjects with Kallmann Syndrome.

Authors:  T-S Jap; C-Y Chiu; J-F Lirng; G-S Won
Journal:  J Endocrinol Invest       Date:  2010-06-04       Impact factor: 4.256

2.  Olfactory phenotypic spectrum in idiopathic hypogonadotropic hypogonadism: pathophysiological and genetic implications.

Authors:  Hilana M Lewkowitz-Shpuntoff; Virginia A Hughes; Lacey Plummer; Margaret G Au; Richard L Doty; Stephanie B Seminara; Yee-Ming Chan; Nelly Pitteloud; William F Crowley; Ravikumar Balasubramanian
Journal:  J Clin Endocrinol Metab       Date:  2011-11-09       Impact factor: 5.958

3.  Commentary: the year in endocrine genetics for basic scientists.

Authors:  William F Crowley
Journal:  Mol Endocrinol       Date:  2011-11-22

Review 4.  The role of prokineticins in the pathogenesis of hypogonadotropic hypogonadism.

Authors:  Ana Paula Abreu; Ursula B Kaiser; Ana Claudia Latronico
Journal:  Neuroendocrinology       Date:  2010-05-21       Impact factor: 4.914

5.  An ancient founder mutation in PROKR2 impairs human reproduction.

Authors:  Magdalena Avbelj Stefanija; Marc Jeanpierre; Gerasimos P Sykiotis; Jacques Young; Richard Quinton; Ana Paula Abreu; Lacey Plummer; Margaret G Au; Ravikumar Balasubramanian; Andrew A Dwyer; Jose C Florez; Timothy Cheetham; Simon H Pearce; Radhika Purushothaman; Albert Schinzel; Michel Pugeat; Elka E Jacobson-Dickman; Svetlana Ten; Ana Claudia Latronico; James F Gusella; Catherine Dode; William F Crowley; Nelly Pitteloud
Journal:  Hum Mol Genet       Date:  2012-07-05       Impact factor: 6.150

Review 6.  Neonatal gonadotropin therapy in male congenital hypogonadotropic hypogonadism.

Authors:  Claire Bouvattier; Luigi Maione; Jérôme Bouligand; Catherine Dodé; Anne Guiochon-Mantel; Jacques Young
Journal:  Nat Rev Endocrinol       Date:  2011-10-18       Impact factor: 43.330

Review 7.  The role of the prokineticin 2 pathway in human reproduction: evidence from the study of human and murine gene mutations.

Authors:  Cecilia Martin; Ravikumar Balasubramanian; Andrew A Dwyer; Margaret G Au; Yisrael Sidis; Ursula B Kaiser; Stephanie B Seminara; Nelly Pitteloud; Qun-Yong Zhou; William F Crowley
Journal:  Endocr Rev       Date:  2010-10-29       Impact factor: 19.871

8.  TAC3/TACR3 mutations reveal preferential activation of gonadotropin-releasing hormone release by neurokinin B in neonatal life followed by reversal in adulthood.

Authors:  Elena Gianetti; Cintia Tusset; Sekoni D Noel; Margaret G Au; Andrew A Dwyer; Virginia A Hughes; Ana Paula Abreu; Jessica Carroll; Ericka Trarbach; Leticia F G Silveira; Elaine M F Costa; Berenice Bilharinho de Mendonça; Margaret de Castro; Adriana Lofrano; Janet E Hall; Erol Bolu; Metin Ozata; Richard Quinton; John K Amory; Susan E Stewart; Wiebke Arlt; Trevor R Cole; William F Crowley; Ursula B Kaiser; Ana Claudia Latronico; Stephanie B Seminara
Journal:  J Clin Endocrinol Metab       Date:  2010-03-23       Impact factor: 5.958

9.  Sexually dimorphic distribution of Prokr2 neurons revealed by the Prokr2-Cre mouse model.

Authors:  Zaid Mohsen; Hosung Sim; David Garcia-Galiano; Xingfa Han; Nicole Bellefontaine; Thomas L Saunders; Carol F Elias
Journal:  Brain Struct Funct       Date:  2017-06-14       Impact factor: 3.270

10.  Prioritizing genetic testing in patients with Kallmann syndrome using clinical phenotypes.

Authors:  Flavia Amanda Costa-Barbosa; Ravikumar Balasubramanian; Kimberly W Keefe; Natalie D Shaw; Nada Al-Tassan; Lacey Plummer; Andrew A Dwyer; Cassandra L Buck; Jin-Ho Choi; Stephanie B Seminara; Richard Quinton; Dorota Monies; Brian Meyer; Janet E Hall; Nelly Pitteloud; William F Crowley
Journal:  J Clin Endocrinol Metab       Date:  2013-03-26       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.